Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients

Summary

This study was 8 weeks randomized, double-blind, placebo-controlled trial to assess the effect of zinc in Atorvastatin treated hyperlipidemic 92 patients. Participants were assessed at baseline, and 8 weeks. Subjects were randomized to receive either atorvastatin+placebo in one arm or atorvastatin +zinc 30mg tablet in another arm daily for 8 weeks. The outcome was the measure of fasting lipid profile, sgpt, serum creatinine at baseline and after 8 weeks following the intervention.

Timeline

Start

2021-05-01

Primary completion

2022-07-10

Completion

2022-07-10

Drugs

Indications